Discover. Oncology最新文献

{"title":"Study on the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109.","authors":"Shang Peng, Yanqiu Li, Yanjun Zhang, Jingting Min, Ran An, Nana Du, Haipeng Li, Xiangcheng Zhen, Fei Chu, Zhenghong Li","doi":"10.1007/s12672-025-03747-x","DOIUrl":"10.1007/s12672-025-03747-x","url":null,"abstract":"<p><strong>Background: </strong>This study was designed to investigate the in vitro and in vivo killing effects of PD-1 antibody-secreting c-Met-targeted CAR-T cells on esophageal cancer cell line ECA109.</p><p><strong>Methods: </strong>We employed the TCGA and GTEx databases to analyze the expression levels of c-Met and PD-L1 in esophageal cancer tissues. Immunohistochemistry was employed to detect the expression of c-Met and PD-L1 in clinical esophageal cancer tissues and adjacent normal tissues. Flow cytometry was employed to verify the expression of c-Met and PD-L1 in ECA109 cells. T cells from healthy volunteers were extracted and activated, and c-Met/PD-1 CAR-T cells were prepared utilizing lentivirus. Flow cytometry was employed to detect the positive rate, subtype, antibody secretion, and anti-apoptotic effects of c-Met/PD-1 CAR-T cells. The experimental group consisted of c-Met/PD-1 CAR-T cells, with c-Met CAR-T and CD19 CAR-T as control groups, and Active T cells as the blank control group. The proliferation, cytokine secretion, and killing ability of CAR-T cells co-cultured with ECA109 cells were assessed utilizing cell viability assays (CCK-8), enzyme-linked immunosorbent assays (ELISA), and lactate dehydrogenase release assays (LDH). In vivo experiments were conducted by subcutaneously injecting ECA109 cells into nude mice to establish tumor-bearing models. CAR-T cells were administered via in situ injection, and changes in body weight and tumor volume were measured. Hematoxylin and eosin (HE) staining was performed on heart, liver, spleen, lung, and kidney tissues from sacrificed mice.</p><p><strong>Results: </strong>c-Met and PD-L1 were highly expressed in esophageal cancer tissues but were low or not expressed in adjacent normal tissues. ECA109 cells expressed c-Met and PD-L1 on their surface. Successfully prepared c-Met/PD-1 CAR-T cells secreted PD-1 antibodies that blocked PD-1 on the surface of CAR-T cells. Under stimulation by c-Met antigens, c-Met/PD-1 CAR-T cells exhibited stronger proliferation, cytokine release, and killing ability. In vivo experiments demonstrated significant tumor inhibition in nude mice treated with c-Met/PD-1 CAR-T cells without evident off-target effects.</p><p><strong>Conclusion: </strong>The c-Met/PD-1 CAR-T cells were successfully constructed and demonstrated significant in vitro and in vivo killing effects on ECA109 esophageal cancer cells.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1933"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Third-generation versus first-generation EGFR tyrosine kinase inhibitors in Asian patients with advanced EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled trials.","authors":"Manzhen Xu, Wei Ding, Linlin Wan, Wenxiong Zhang","doi":"10.1007/s12672-025-03767-7","DOIUrl":"10.1007/s12672-025-03767-7","url":null,"abstract":"<p><strong>Background: </strong>Third-generation EGFR-TKIs (TGETs) have demonstrated improved clinical outcomes compared to first-generation EGFR-TKIs (FGETs) in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Nonetheless, the comparative safety and efficacy of TGETs as a first-line option for Asian patients with advanced EGFR-mutant NSCLC remain unclear. This meta-analysis aims to compare the survival outcomes, response rates, and adverse events (AEs) of TGETs versus FGETs in this population.</p><p><strong>Methods: </strong>We systematically searched 6 databases for eligible phase 3 randomized controlled trials (RCTs). Eligible studies included those comparing TGETs with FGETs in previously untreated Asian patients with EGFR-mutant advanced NSCLC. Pooled hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS), risk ratios (RRs) for response rates, and AEs were calculated and analyzed.</p><p><strong>Results: </strong>Seven phase 3 RCTs comprising 2434 Asian patients were included. TGETs significantly improved PFS (HR: 0.47 [0.42, 0.52], P < 0.00001) and central nervous system-PFS (HR: 0.57 [0.40, 0.80], P = 0.001) compared to FGETs. A trend toward improved OS was also observed with TGETs (HR: 0.88 [0.75, 1.03], P = 0.10). The advantages of PFS in the TGET group were confirmed in all subgroups. The objective response rate (ORR) (RR: 1.05 [1.01, 1.09], P = 0.03) and duration of response (DOR) (HR: 0.41 [0.34, 0.48], P < 0.00001) were also better in the TGET group. Total/grade 3-5 treatment-emergent AEs (TEAEs) and Total/grade 3-5 treatment-related AEs (TRAEs) were similar between the two groups. The top 3 TEAEs of TGET group were diarrhea (31.72%), rash (30.90%), and platelet count decreased (27.97%).</p><p><strong>Conclusion: </strong>Compared with FGETs, TGETs significantly improve PFS, CNS control, response outcomes, and maintain a comparable safety profile for Asian patients with advanced EGFR-mutated NSCLC.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1932"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of promising lung cancer targets from human plasma proteins via Mendelian randomization.","authors":"Xiao-Dong Shao, Zhou-Lin Miao, Wei-Jie Yu","doi":"10.1007/s12672-025-03746-y","DOIUrl":"10.1007/s12672-025-03746-y","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer (LC) is the most prevalent form of malignant neoplasm globally, as well as the major cause of cancer-related death. Identifying effective pharmaceutical targets is paramount in advancing the development of treatment modalities for LC.</p><p><strong>Method: </strong>Protein-wide Mendelian randomization (MR) was used in this study. The present study collated data on plasma proteins from a protein quantitative trait loci (pQTL) study with a total of 4907 individuals. Genetic associations with LC were obtained from GWAS, including 3791 cases and 489012 controls. Integration of pQTL and LC genome-wide association study (GWAS) data was employed to identify candidate proteins. MR used single nucleotide polymorphisms (SNPs) as a genetic tool to estimate the causal effect of exposure on the outcome, while reverse Mendelian randomization was performed to assess the presence of false positives. The present study utilized these approaches to evaluate the causal relationship between plasma proteins and LC. Finally, protein-protein interaction (PPI) and functional enrichment analyses were performed to illustrate potential links between proteins and current LC drugs. Finally, drug prediction and molecular docking were performed to predict drugs and explored the expression distribution of key genes by single-cell sequencing.</p><p><strong>Result: </strong>We identified 46 plasma proteins that are strongly associated with LC Fifteen of these proteins have protective effects. Among them, MMP8(OR = 0.87, 95%CI:0.78-0.97, p = 0.013) had the most significant protective effect. In contrast, 31 proteins increased the risk of LC. IL36A༈OR = 1.20, 95%CI:1.041-1.38, p = 0.012) exhibited the most significant MR result. Notably, COL2A1, MMP19 showed reverse causality. This was further verified by enrichment analysis, which confirmed the causal effect of these proteins. Additionally, the researchers utilized the DSigDB database to predict potentially effective intervening drugs, identifying nine possible candidates. Molecular docking showed that the drugs bind very much to the proteins. KDR and ANGPTL4 are abundantly expressed in lung tissue and are differentially expressed between cells.</p><p><strong>Conclusion: </strong>The present study has revealed six potential drug targets for the treatment of LC. Drugs designed to target these proteins will be more likely to attain success in clinical trials and are expected to assist in the development of LC drugs and reduce drug development costs.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1927"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage-mediated delivery of ganciclovir nanocomplexes inhibits the pathogenicity of Kaposi's sarcoma-associated herpesvirus.","authors":"Haopeng Tan, Lixia Yao, Runa Zhang, Mengchan Ye, Shanzhe Shi, Jinli Zhang, Jianyu Xu, Dongdong Cao, Fangling Li, Dongmei Li","doi":"10.1007/s12672-025-03772-w","DOIUrl":"10.1007/s12672-025-03772-w","url":null,"abstract":"<p><p>Kaposi's sarcoma-associated herpesvirus (KSHV), a member of the γ-herpesvirus family, is associated with the development of various malignancies. Ganciclovir (GCV) is a competitive inhibitor of DNA and can inhibit the synthesis of KSHV viral DNA polymerase. However, the water solubility of GCV makes it difficult to cross the cell membrane. Although nanocarriers are effective in delivering drugs into cells, they still face challenges in penetrating the dense tissue protected by the mucosal barrier. To address this, we developed macrophage-camouflaged nanoparticles as a drug delivery system, leveraging the innate tropism of macrophages to enhance tissue infiltration and therapeutic outcomes. This approach not only improves drug bioavailability but also minimizes off-target toxicity. In this study, we established an in vitro macrophage inflammation model to mimic the in vivo inflammatory microenvironment and employed ZIF-8 nanoparticles to encapsulate GCV, with hyaluronic acid (HA) as a targeting ligand. The in vivo and in vitro safety evaluations confirmed its excellent biocompatibility. The co-culturing experiment of induced macrophages loaded with nanodrugs with KSHV-positive cells showed that it can restrain proliferation and migration ability of KSHV-positive cells, and also reduce the expression of KSHV pathogenic genes. Collectively, our findings proposed a novel strategy utilizing macrophage-mediated delivery of HA/GCV@ZIF-8 nanomaterials to combat KSHV infection.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1943"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-cancer analysis of role of LOXL4 and experiment validation in osteosarcoma.","authors":"Wenjie Chen, Fujie Xie, Jie Lv, Dixi Huang, Ronghao Zhong, Zhijia Wen, Jiangsen Sun, Shaowei Zheng, Weile Liu, Haobo Zhong, Shoubin Huang","doi":"10.1007/s12672-025-03761-z","DOIUrl":"10.1007/s12672-025-03761-z","url":null,"abstract":"<p><strong>Background: </strong>Osteosarcoma is an aggressive bone malignancy with high metastatic potential and poor prognosis, primarily affecting children and adolescents. Although lysyl oxidase-like 4 (LOXL4) has been implicated in tumor progression, its functional role and mechanistic contributions in Osteosarcoma remain unclear.</p><p><strong>Methods: </strong>We performed integrated bioinformatics analysis using GTEx, TARGET, and TCGA datasets to evaluate LOXL4 expression and prognostic significance across cancers. Genetic alteration, immune infiltration, and RNA methylation analysis were carried to explore the different roles of LOXL4 in tumors. Functional assays, including Cell Counting Kit-8 (CCK-8), colony formation, and Matrigel transwell assays, were conducted in Osteosarcoma cell lines. Besides, western blotting and gene set enrichment analysis (GSEA) were used to explore LOXL4's mechanistic roles.</p><p><strong>Results: </strong>LOXL4 was significantly upregulated in Osteosarcoma tissues and associated with poor patient survival. Pan-cancer analysis revealed LOXL4 is upregulated in multiple cancer types and exhibits tumor-type-specific genetic alteration patterns, most frequently mutated in melanoma and amplified in endometrial carcinoma. Besides, LOXL4 expression significantly correlated with immune infiltration levels, the expression of immune checkpoint molecules, and RNA methylation across multiple cancers. Functional experiments demonstrated that LOXL4 knockdown suppressed cell proliferation, invasion, and epithelial-mesenchymal transition (EMT), whereas LOXL4 overexpression enhanced these malignant phenotypes. Mechanistically, LOXL4 activated the Wnt/β-catenin signaling pathway. Inhibition of Wnt/β-catenin signaling with XAV-939 reversed LOXL4-induced oncogenic effects.</p><p><strong>Conclusion: </strong>LOXL4 promotes Osteosarcoma progression via Wnt/β-catenin-mediated EMT and cell proliferation. Its pan-overexpression and associations with the tumor immune microenvironment underscore its potential as a therapeutic target. Targeting LOXL4 or its downstream pathway may offer novel therapeutic strategies for Osteosarcoma.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1926"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Left-sided clear cell renal cell carcinoma initially presenting with isolated abdominal wall metastasis: a case report.","authors":"Ji Yu, ZhongRu Sun, Qingyu Chen, Ming Yin","doi":"10.1007/s12672-025-03741-3","DOIUrl":"10.1007/s12672-025-03741-3","url":null,"abstract":"<p><p>Isolated abdominal wall metastasis of clear cell renal cell carcinoma is exceedingly rare. We report a case where isolated abdominal wall metastasis served as the initial manifestation while the primary renal carcinoma remained occult. The patient was admitted for a right abdominal wall mass and underwent mass excision, with postoperative pathology unexpectedly revealing metastatic clear cell carcinoma. Subsequent systematic imaging evaluation identified clear cell renal cell carcinoma in the left kidney, leading to radical left nephrectomy. This case comprehensively presents the diagnostic and therapeutic process of renal cell carcinoma with atypical site metastasis, which will enhance clinicians' ability to recognize atypical metastases of renal cell carcinoma, thereby facilitating better identification of such lesions and further guiding treatment prognosis.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1938"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of prognostic genes for lung adenocarcinoma prognosis based on PANoptosis-related genes.","authors":"Guo-Qiang Song, Yu-Ying Wu, Tian-Li He, Ke-Jie Ji, Yi-Meng Duan, Jia-Wen Zhang, Sheng-Qi Fei, Guo-Qiang Hu","doi":"10.1007/s12672-025-03690-x","DOIUrl":"10.1007/s12672-025-03690-x","url":null,"abstract":"<p><strong>Background: </strong>PANoptosis, a newly identified form of cell death, has been linked to both the destruction of cancer cells and the regulation of antitumor immunity. This study aimed to establish a PANoptosis-related signature associated with lung adenocarcinoma (LUAD), highlighting its role in LUAD pathogenesis.</p><p><strong>Methods: </strong>Transcriptome data from the TCGA-LUAD dataset were analyzed to identify PANoptosis-related differentially expressed genes (PANR-DEGs). A LUAD gene signature was developed using Cox regression and LASSO analyses. The study also evaluated somatic mutations, the immune microenvironment, and immunotherapy potential across two risk groups. Additionally, prognostic gene expression was validated clinically by reverse transcription-quantitative PCR (RT-qPCR).</p><p><strong>Results: </strong>The TCGA-LUAD dataset revealed 520 PANR-DEGs. A prognostic signature based on six key genes-CDCP1, CLIC6, FURIN, KRT6A, MFI2, and P2RY13-was constructed. Prognostic analysis indicated that pathological T and N statuses, along with the risk score, could serve as independent prognostic markers. Significant differences in the immune microenvironment were observed between the two risk groups, with TP53 showing the highest mutation frequency. Drug sensitivity assays suggested that the PANoptosis-related gene signature could serve as a predictive tool for therapy. Elevated expression levels of CDCP1, CLIC6, FURIN, KRT6A, and MFI2 were observed in tumor tissues compared to normal tissues. RT-qPCR results confirmed the findings from the bioinformatic analysis.</p><p><strong>Conclusion: </strong>A prognostic signature composed of CDCP1, CLIC6, FURIN, KRT6A, MFI2, and P2RY13, based on PANR-DEGs, provides a theoretical framework and reference for further LUAD research.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1935"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis in AML: nanoparticles, biomarkers, and immune rewiring for therapeutic breakthroughs.","authors":"Farzaneh Tavakoli, Mohammad Ali Araskhan, Fatemeh Karimpour, Hamed Soleimani Samarkhazan, Hoda Hasheminasab, Elham Roshandel, Nader Vazifeh Shiran, Ali Dehghanifard, Mohammad Hossein Mohammadi","doi":"10.1007/s12672-025-03777-5","DOIUrl":"10.1007/s12672-025-03777-5","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1937"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in the study of FAT family genes in lung cancer.","authors":"Xiaoyue Deng, Zhiqiong Yu, Weihua Hu","doi":"10.1007/s12672-025-03752-0","DOIUrl":"10.1007/s12672-025-03752-0","url":null,"abstract":"<p><p>The FAT atypical cadherin (FAT) gene family comprises FAT atypical cadherin 1 (FAT1), 2 (FAT2), 3 (FAT3), and 4 (FAT4). These transmembrane adhesion proteins are essential for regulating cell polarity, adhesion, and migration, and are involved in multiple signaling transduction pathways. With the advancement of tumor genomics research, the mutation, expression, and functional regulation of FAT in various cancer types have been elucidated, particularly in non-small cell lung cancer, where FAT has significant biological implications and promising clinical applications. FAT1, a frequently mutated member of the family, participates in remodeling the immune microenvironment via the Wnt/β-catenin, Hippo, and transforming growth factor-beta (TGF-β) pathways. It also influences immune cell infiltration, immune checkpoint expression, and tumor mutational burden, thereby affecting the efficacy of immunotherapy. FAT2 influences cell migration and immune response by modulating cytoskeletal dynamics and the expression of immunochemokines. The non-coding RNA circular RNA FAT3 (circFAT3) may contribute to tumor growth and metastasis. FAT4, a major upstream regulator of the Hippo signaling pathway, inhibits Yes-associated protein/transcriptional coactivator with PDZ-binding motif, maintains cell polarity, and plays multiple roles by regulating the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathways and promoting anti-immune escape. This study comprehensively integrated and analyzed research results on the characteristics of the FAT gene family in lung cancer, focusing on its mutations, signaling pathways, and immunological roles, as well as its clinical significance in terms of prognosis. This study provides theoretical support and references for the development of targeted therapeutic strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1929"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the global research status and intellectual map of cancer and immunosuppressants.","authors":"Tianyi Yuan, Yamin Zhao, Yunna Ma, Yue Ben, Tianqi Wu, Hongrun Shi, Jun Pu, Jue Gu","doi":"10.1007/s12672-025-03781-9","DOIUrl":"10.1007/s12672-025-03781-9","url":null,"abstract":"<p><strong>Background: </strong>The use of immune checkpoint inhibitors (ICIs) has significantly advanced cancer therapy, improving survival rates and prognosis for many patients. This study employs bibliometric methods to explore the current state and future trends in the field of immunosuppressants and cancer treatment.</p><p><strong>Methods: </strong>Data were retrieved from the Science Citation Index Expanded for articles and reviews published between 2014 and 2024 in the Web of Science database. 2,352 records were analyzed using CiteSpace, VOSviewer, R software, and Microsoft Excel. The focus was on publication trends, citations, co-citation networks, keyword co-occurrence, and collaborative networks.</p><p><strong>Results: </strong>The study identified a steady increase in publications and citations, with an average annual growth rate of 3.93%. The United States and China were the leading countries in research output, while the University of Texas MD Anderson Cancer Center and Harvard Medical School were key institutions. Research hotspots included ICIs, tumor microenvironment, and immune-related adverse events. Interdisciplinary collaboration was highlighted as crucial for advancing the field.</p><p><strong>Conclusions: </strong>The growing body of research on cancer and immunosuppressants highlights the need for optimizing immunotherapy protocols, managing drug resistance, and exploring the potential of immunosuppressants in cancer treatment. Strengthening international collaboration is vital for translating research findings into clinical practice and improving patient outcomes. Despite the comprehensive analysis, the study's reliance on the WoSCC database and English-language publications may limit the generalizability of findings.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1930"},"PeriodicalIF":2.9,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145336580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}